HPP 737
Alternative Names: HPP-737Latest Information Update: 16 Aug 2024
At a glance
- Originator vTv Therapeutics LLC
- Developer Newsoara Biopharma; vTv Therapeutics LLC
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Atopic dermatitis; Chronic obstructive pulmonary disease; Psoriasis